Rebecca Hubbard, PhD, and Qi Long, PhD, are co-authors on this new JAMA Oncology paper that finds solid-tumor cancer patients ineligible for clinical trials receive immunotherapy at greater rates — despite lack of benefits.
Rebecca Hubbard, PhD, and Qi Long, PhD, are co-authors on this new JAMA Oncology paper that finds solid-tumor cancer patients ineligible for clinical trials receive immunotherapy at greater rates — despite lack of benefits.